-
-
-
-
-
-
-
Baird Reiterates Outperform Rating on Mirum Pharmaceuticals (MIRM)
-
-
-
-
-
-
-
Mirum Pharmaceuticals (MIRM) Reiterated at Overweight by Cantor Fitzgerald
-
-
-
-
-
-
-
Mirum Pharmaceuticals (MIRM) PT Lowered to $118 at Leerink Partners
-
-
-
-
-
-
-
Mirum Pharmaceuticals (MIRM) Reiterated at Market Outperform: 'Top Pick' at Citizens
-
-
-
-
-
-
-
Mirum (MIRM) PT Raised to $140 at Citizens: Outperformance Expected
-
-
-
-
-
-
-
Morgan Stanley: 'we view the HDV program as promising and we view the transaction as a good fit for Mirum'
-
-
-
-
-
-
-
Mirum Pharmaceuticals, Inc. (MIRM) Files Mixed Shelf
-
408,193 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

